Many think the next standard cancer treatment will pair two innovations.
Merck & Co.'s cancer immunotherapy Keytruda is one of the pharmaceutical industry's biggest successes. The drug's arrival in 2014 introduced a new way of treating cancer and, over time, it became ...
SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...
COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when ...
Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results